Compounds > pioglitazone
Page last updated: 2024-08-16

pioglitazone and epidermal growth factor

pioglitazone has been researched along with epidermal growth factor in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boegehold, MA; Dubey, RK; Kotchen, TA; Reddy, SR; Zhang, HY1
Kashiwagi, A; Kikkawa, R; Maegawa, H; Obata, T; Pillay, TS1
Achanzar, WE; Burgun, JJ; Car, BD; Chen, SJ; Cosma, GN; Dominick, MA; Foster, WR; French, MH; Gullo, R; Kozlosky, JC; Marthaler, LT; Moyer, CF; Rhodes, JW; Watson, LM; White, MR1
Costa Oliveira, A; de Lima, Mdo C; de Oliveira Cipriano Torres, D; dos Santos Gomes, FO; dos Santos Silva, B; dos Santos, LA; Lima Ribeiro, E; Peixoto, CA; Pitta, Ida R; Soares e Silva, AK1
Hou, Y; Jin, J; Shi, J; Xu, Y; You, M; Zhang, W1

Other Studies

5 other study(ies) available for pioglitazone and epidermal growth factor

ArticleYear
Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats.
    The American journal of physiology, 1993, Volume: 265, Issue:4 Pt 2

    Topics: Animals; Arterioles; Blood Pressure; Cell Division; Epidermal Growth Factor; Hypertension; Hypoglycemic Agents; Insulin; Kidney; Male; Muscle, Smooth; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Sodium Chloride; Thiazoles; Thiazolidinediones; Thymidine

1993
High glucose-induced abnormal epidermal growth factor signaling.
    Journal of biochemistry, 1998, Volume: 123, Issue:5

    Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Membrane; Cells, Cultured; Cytosol; Epidermal Growth Factor; Fibroblasts; Glucose; Humans; Hypoglycemic Agents; Isoenzymes; Phosphorylation; Pioglitazone; Protein Tyrosine Phosphatases; Rats; Receptor, Insulin; RNA, Messenger; Signal Transduction; Thiazoles; Thiazolidinediones

1998
Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
    Toxicology and applied pharmacology, 2007, Sep-15, Volume: 223, Issue:3

    Topics: Acids; Animals; Cell Proliferation; Diet; Epidermal Growth Factor; Immunohistochemistry; Male; Peroxisome Proliferator-Activated Receptors; Phosphorylation; Pioglitazone; Rats; Rats, Sprague-Dawley; Signal Transduction; Thiazolidinediones; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium

2007
LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Animals; Cyclooxygenase 2; Diet, High-Fat; Disease Models, Animal; Epidermal Growth Factor; I-kappa B Proteins; Inflammation; Interleukin-6; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-KappaB Inhibitor alpha; Nitric Oxide Synthase Type II; Non-alcoholic Fatty Liver Disease; Pioglitazone; Receptors, LDL; Thiazolidinediones; Triglycerides

2015
Pioglitazone inhibits EGFR/MDM2 signaling-mediated PPARĪ³ degradation.
    European journal of pharmacology, 2016, Nov-15, Volume: 791

    Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Humans; Phosphorylation; Pioglitazone; PPAR gamma; Proteolysis; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Thiazolidinediones; Ubiquitination

2016